WTX-124 is under clinical development by Werewolf Therapeutics and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase I drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WTX-124’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WTX-124 overview
WTX-124 is under development for the treatment of solid tumors, colon carcinoma, advanced or metastatic renal cell carcinoma and advanced or metastatic cutaneous malignant melanoma, adenocarcinoma of the gastroesophageal junction, transitional cell carcinoma (urothelial cell carcinoma), hepatocellular carcinoma, non-small cell lung cancer, cutaneous squamous cell carcinoma (cscc). It is novel receptor agonists for cancer immunotherapy. It is developed based on PREDATOR technology. It acts by targeting IL2Rb/IL2Rg. The drug candidate is a systemically-delivered conditionally-activated Interleukin-2 (IL-2) INDUKINE molecule
Werewolf Therapeutics overview
Werewolf Therapeutics is a biopharmaceutical company that discovers and develops treatments for cancer. The company investigating WTX-124, a conditionally activated interleukin-2 (IL-2) based drug to treat multiple tumor types and WTX-330 and WTX-613 drugs administered as monotherapies for refractory and immunologically unresponsive tumors. Werewolf Therapeutics utilizes its proprietary Predator protein engineering technology platform to identify, design, optimize and validate immuno-oncology, autoimmune and inflammatory disease product candidates. It’s protein engineering technology integrates protein design elements to improve activity, stability and tumor selectivity within a single molecule. Werewolf Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of WTX-124’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
